Press release from Companies
Published: 2014-10-21 12:25:11
Correction of the headline: the headline has been updated to clarify that the patent now granted does not relate to Foxy-5 but instead to Foxy-5 related peptide WntResearch AB wishes to inform that -as the company announced in June, and commented further on in September - the European Patent Office has earlier informed the company that it intends to grant patent No. 1 888 628 concerning peptides related to the company’s product Foxy-5. All remaining issues have now been dealt with, and accordingly the European Patent Office issued on 16 October 2014 a decision to grant the patent. At the same time, the European Patent Office informed the company that the patent will enter into force on 12 November 2014.
For additional information please contact: Nils Brünner, VD E-post: firstname.lastname@example.org Telefon: + 45 2614 4708 Om WntResearch WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer.WntResearch has one drug candidate in clinical phase I – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.